Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
71
GLSI Quote, Financials, Valuation and Earnings
Last price:
$27.62
Seasonality move
:
-14.06%
Day range:
$24.75 - $28.14
52-week range:
$7.78 - $34.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
178.31x
Volume:
190.5K
Avg. volume:
501.3K
1-year change:
139.12%
Market cap:
$389.6M
Revenue:
--
EPS (TTM):
-$1.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -- | -- | -- | $47.50 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
BMY
Bristol Myers Squibb Co.
|
$12.3B | $1.20 | -2.92% | 19.59% | $61.76 |
|
JANX
Janux Therapeutics, Inc.
|
$76.9K | -$0.64 | 599.64% | -85.41% | $61.44 |
|
MRNA
Moderna, Inc.
|
$623.9M | -$2.64 | 121.94% | -16.92% | $42.05 |
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
$535K | -$2.00 | 104.67% | -87% | $17.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
$28.12 | $47.50 | $389.6M | -- | $0.00 | 0% | -- |
|
ABT
Abbott Laboratories
|
$116.26 | $133.39 | $202.2B | 31.28x | $0.63 | 2.06% | 4.59x |
|
BMY
Bristol Myers Squibb Co.
|
$61.10 | $61.76 | $124.4B | 17.67x | $0.63 | 4.08% | 2.59x |
|
JANX
Janux Therapeutics, Inc.
|
$13.80 | $61.44 | $830M | -- | $0.00 | 0% | 83.68x |
|
MRNA
Moderna, Inc.
|
$51.71 | $42.05 | $20.2B | -- | $0.00 | 0% | 10.35x |
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
$2.96 | $17.60 | $3.8M | 15.22x | $0.00 | 0% | 1.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -0.625 | -- | 2.35x |
|
ABT
Abbott Laboratories
|
21.33% | 0.141 | 6.97% | 1.05x |
|
BMY
Bristol Myers Squibb Co.
|
71.85% | -0.406 | 44.08% | 0.88x |
|
JANX
Janux Therapeutics, Inc.
|
2.27% | 0.739 | 1.54% | 35.54x |
|
MRNA
Moderna, Inc.
|
13.11% | 0.952 | 11.33% | 3.01x |
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
3.36% | 0.452 | 1.32% | 2.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -$4.2M | -781.94% | -781.94% | -- | -$2.7M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
BMY
Bristol Myers Squibb Co.
|
$8.3B | $3.6B | 10.38% | 39.9% | 29.05% | $1.6B |
|
JANX
Janux Therapeutics, Inc.
|
$9.5M | -$35.3M | -10.68% | -10.94% | -352.51% | -$12.9M |
|
MRNA
Moderna, Inc.
|
$159M | -$857M | -26.82% | -29.19% | -126.4% | $891M |
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
-$9.1K | -$2.3M | -186.16% | -193.16% | -439.94% | -$2.1M |
Greenwich LifeSciences, Inc. vs. Competitors
-
Which has Higher Returns GLSI or ABT?
Abbott Laboratories has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of 15.71%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About GLSI or ABT?
Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 68.92%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 14.73%. Given that Greenwich LifeSciences, Inc. has higher upside potential than Abbott Laboratories, analysts believe Greenwich LifeSciences, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.2 0 0 ABTAbbott Laboratories16 7 0 -
Is GLSI or ABT More Risky?
Greenwich LifeSciences, Inc. has a beta of 1.465, which suggesting that the stock is 46.49% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.
-
Which is a Better Dividend Stock GLSI or ABT?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.06% to investors and pays a quarterly dividend of $0.63 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GLSI or ABT?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than Abbott Laboratories's net income of $1.8B. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 31.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 4.59x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M ABTAbbott Laboratories4.59x 31.28x $11.5B $1.8B
-
Which has Higher Returns GLSI or BMY?
Bristol Myers Squibb Co. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of 8.69%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M BMYBristol Myers Squibb Co.66.24% $0.53 $65.6B -
What do Analysts Say About GLSI or BMY?
Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 68.92%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $61.76 which suggests that it could grow by 1.08%. Given that Greenwich LifeSciences, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Greenwich LifeSciences, Inc. is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.2 0 0 BMYBristol Myers Squibb Co.6 18 1 -
Is GLSI or BMY More Risky?
Greenwich LifeSciences, Inc. has a beta of 1.465, which suggesting that the stock is 46.49% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.296%.
-
Which is a Better Dividend Stock GLSI or BMY?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.08% to investors and pays a quarterly dividend of $0.63 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GLSI or BMY?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 2.59x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M BMYBristol Myers Squibb Co.2.59x 17.67x $12.5B $1.1B
-
Which has Higher Returns GLSI or JANX?
Janux Therapeutics, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -243.13%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M JANXJanux Therapeutics, Inc.94.99% -$0.39 $999.2M -
What do Analysts Say About GLSI or JANX?
Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 68.92%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $61.44 which suggests that it could grow by 345.2%. Given that Janux Therapeutics, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.2 0 0 JANXJanux Therapeutics, Inc.14 1 0 -
Is GLSI or JANX More Risky?
Greenwich LifeSciences, Inc. has a beta of 1.465, which suggesting that the stock is 46.49% more volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GLSI or JANX?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or JANX?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Janux Therapeutics, Inc. quarterly revenues of $10M. Greenwich LifeSciences, Inc.'s net income of -$4.2M is higher than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 83.68x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M JANXJanux Therapeutics, Inc.83.68x -- $10M -$24.3M
-
Which has Higher Returns GLSI or MRNA?
Moderna, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -121.83%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Moderna, Inc.'s return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M MRNAModerna, Inc.23.45% -$2.11 $10B -
What do Analysts Say About GLSI or MRNA?
Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 68.92%. On the other hand Moderna, Inc. has an analysts' consensus of $42.05 which suggests that it could fall by -18.68%. Given that Greenwich LifeSciences, Inc. has higher upside potential than Moderna, Inc., analysts believe Greenwich LifeSciences, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.2 0 0 MRNAModerna, Inc.2 17 1 -
Is GLSI or MRNA More Risky?
Greenwich LifeSciences, Inc. has a beta of 1.465, which suggesting that the stock is 46.49% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.
-
Which is a Better Dividend Stock GLSI or MRNA?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or MRNA?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $678M. Greenwich LifeSciences, Inc.'s net income of -$4.2M is higher than Moderna, Inc.'s net income of -$826M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 10.35x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M MRNAModerna, Inc.10.35x -- $678M -$826M
-
Which has Higher Returns GLSI or SXTP?
60 Degrees Pharmaceuticals, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -438.1%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16%.
Company Gross Margin Earnings Per Share Invested Capital GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M -
What do Analysts Say About GLSI or SXTP?
Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 68.92%. On the other hand 60 Degrees Pharmaceuticals, Inc. has an analysts' consensus of $17.60 which suggests that it could grow by 494.6%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLSIGreenwich LifeSciences, Inc.2 0 0 SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 -
Is GLSI or SXTP More Risky?
Greenwich LifeSciences, Inc. has a beta of 1.465, which suggesting that the stock is 46.49% more volatile than S&P 500. In comparison 60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GLSI or SXTP?
Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 60 Degrees Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. 60 Degrees Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLSI or SXTP?
Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than 60 Degrees Pharmaceuticals, Inc. quarterly revenues of $528.6K. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while 60 Degrees Pharmaceuticals, Inc.'s PE ratio is 15.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 1.48x for 60 Degrees Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M SXTP60 Degrees Pharmaceuticals, Inc.1.48x 15.22x $528.6K -$2.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.96% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 10.47% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 6.68% over the past day.
